BeOne Medicines (ONC) Research & Development (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Research & Development of $541.2 million for Q1 2026, up 12.31% year-over-year from $481.9 million in Q1 2025, and down 12.06% quarter-over-quarter from $615.4 million in Q4 2025.
BeOne Medicines (ONC) Research & Development (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Research & Development for 12 consecutive years, with $541.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 12.31% year-over-year to $541.2 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 11.68% YoY), while the FY2025 annual figure was $2.1 billion, up 9.86% from the prior year.
- Research & Development fell to $541.2 million in Q1 2026 per ONC's latest filing, from $615.4 million in the prior quarter.
- Across five years, Research & Development topped out at $615.4 million in Q4 2025 and bottomed at $378.2 million in Q2 2022.
- Historically, Research & Development has averaged $474.1 million across 5 years, with a median of $460.6 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development jumped 180.18% — and 2025, when it rose 4.61%.
- BeOne Medicines' Research & Development stood at $446.0 million in 2022, then advanced by 10.75% to $494.0 million in 2023, then increased by 9.72% to $542.0 million in 2024, then grew by 13.54% to $615.4 million in 2025, then declined by 12.06% to $541.2 million in 2026.
- Business Quant data shows ONC's Research & Development at $541.2 million in Q1 2026, $615.4 million in Q4 2025, and $523.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 612.28 Mn |
| Mar 31, 2026 | 541.22 Mn |
| Dec 31, 2025 | 615.42 Mn |
| Sep 30, 2025 | 523.66 Mn |
| Jun 30, 2025 | 524.90 Mn |
| Mar 31, 2025 | 481.89 Mn |
| Dec 31, 2024 | 542.01 Mn |
| Sep 30, 2024 | 496.18 Mn |
| Jun 30, 2024 | 454.47 Mn |
| Mar 31, 2024 | 460.64 Mn |
| Dec 31, 2023 | 493.99 Mn |
| Sep 30, 2023 | 453.26 Mn |
| Jun 30, 2023 | 422.76 Mn |
| Mar 31, 2023 | 408.58 Mn |
| Dec 31, 2022 | 446.02 Mn |
| Sep 30, 2022 | 426.36 Mn |
| Jun 30, 2022 | 378.21 Mn |
| Mar 31, 2022 | 389.92 Mn |
| Dec 31, 2021 | -556.29 Mn |
| Sep 30, 2021 | 351.94 Mn |